Updated Jul 16, 2026
Kelly Jared has filed 1 SEC Form 4 filing across 1 company in the last 90 days — buying. Lifetime open-market purchases: $34K. Historical track record: 5/5 stars across 3 tracked purchases.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★★★★★ (5/5) |
|---|---|
| Total purchases tracked | 3 |
| Purchases with forward-return data | 3 |
| 30-day win rate | 10000% |
| 90-day win rate | 6667% |
| Avg 5-day return | +1155.33% |
| Avg 30-day return | +1476.60% |
| Avg 90-day return | -220.09% |
| Best 30-day return | +1980.35% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-13 | ONCY | ONCOLYTICS BIOTECH INC | P — Open-market purchase | 5.0K | $0.96 | $5K |
| 2026-02-13 | ONCY | ONCOLYTICS BIOTECH INC | P — Open-market purchase | 29.5K | $0.84 | $25K |
| 2026-02-13 | ONCY | ONCOLYTICS BIOTECH INC | P — Open-market purchase | 5.6K | $0.84 | $5K |
Kelly Jared is a corporate insider — currently tracked as Chief Executive Officer, Director of ONCOLYTICS BIOTECH INC (ONCY). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 3 open-market purchases ($34K) and 0 open-market sales () across all tracked filings.
Across 3 tracked purchases, Kelly Jared averaged +1476.6% avg 30-day return with a 10000% 30-day win rate. InsiderAlpha rates the track record at 5/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Kelly Jared profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.